Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Fulgent Genetics Inc.

    NASDAQ: FLGT · Real-Time Price · USD
    20.48
    3.23 (18.72%)
    At close: May 02, 2025, 3:59 PM
    20.13
    -1.71%
    After-hours: May 02, 2025, 05:46 PM EDT
    18.72%
    Bid 19.73
    Market Cap 632.13M
    Revenue (ttm) 283.47M
    Net Income (ttm) -42.71M
    EPS (ttm) -1.41
    PE Ratio (ttm) -14.52
    Forward PE -27.6
    Analyst Hold
    Ask 20.53
    Volume 771,696
    Avg. Volume (20D) 468,588
    Open 18.20
    Previous Close 17.25
    Day's Range 17.93 - 20.90
    52-Week Range 14.57 - 25.11
    Beta 1.37

    About FLGT

    Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children i...

    [Read more]
    Industry Medical - Diagnostics & Research
    Sector Healthcare
    IPO Date Sep 29, 2016
    Employees 1,313
    Stock Exchange NASDAQ
    Ticker Symbol FLGT
    Website https://www.fulgentgenetics.com
    Full Company Profile

    Analyst Forecast

    According to 1 analyst ratings, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $16, which is a decrease of -21.88% from the latest price.

    Stock Forecasts

    Earnings Surprise

    Fulgent Genetics has released their quartely earnings on May 2, 2025:
  • Revenue of $73.46M exceeds estimates by $2.2M, with 13.92% YoY growth.
  • EPS of 0.04 exceeds estimates by 0.22, with 500.00% YoY growth.

    • Next Earnings Release

    Fulgent Genetics Inc. is scheduled to release its earnings on May 2, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    17 hours ago
    Fulgent Genetics shares are trading higher after t... Unlock content with Pro Subscription
    news image

    1 day ago · seekingalpha.com

    Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

    Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

    news image

    15 hours ago · zacks.com

    Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates

    Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ag...

    news image

    17 hours ago · businesswire.com

    Fulgent Reports First Quarter 2025 Financial Results

    EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

    news image

    3 weeks ago · businesswire.com

    Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

    EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

    news image

    4 weeks ago · seekingalpha.com

    Stock Picks From Seeking Alpha's March 2025 New Analysts

    In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

    news image

    1 month ago · seekingalpha.com

    Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

    CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a sig...

    news image

    2 months ago · seekingalpha.com

    Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

    Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Com...

    news image

    2 months ago · fool.com

    Fulgent Genetics Revenue Tops Estimates

    Laboratory services and therapeutic development specialist Fulgent Genetics (FLGT 0.53%) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. ...

    news image

    2 months ago · zacks.com

    Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates

    Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $0.28 per share a yea...

    news image

    2 months ago · businesswire.com

    Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

    EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

    Add to Watchlist